



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/426561/2011

European Medicines Agency decision P/120/2011

of 7 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for ombrabulin (EMA-000800-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/120/2011

of 7 June 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral for ombrabulin (EMA-000800-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Sanofi-aventis recherche & developpement 10 December 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 April 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ombrabulin, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ombrabulin, concentrate for solution for infusion, intravenous use,, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Sanofi-aventis recherche & developpement, 1 avenue Victor Basch, 91300 - Massy, France.

Done at London, 7 June 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/178413/2011

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-000800-PIP01-09

Scope of the application

Active substance(s):

Ombrabulin

Condition(s):

Treatment of rhabdomyosarcoma

Treatment of non-rhabdomyosarcoma soft tissue sarcoma

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Sanofi-aventis recherche & developpement

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sanofi-aventis recherche & developpement submitted for agreement to the European Medicines Agency on 10 December 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 18 February 2010.

Supplementary information was provided by the applicant on 4 February 2011.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 20 April 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Conditions: Treatment of rhabdomyosarcoma and treatment of non-rhabdomyosarcoma soft tissue sarcoma

2.1.1. Indication(s) targeted by the PIP

- Treatment of metastatic or locally advanced rhabdomyosarcoma soft tissue sarcoma;
- Treatment of relapsed / progressive non-rhabdomyosarcoma soft tissue sarcoma.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	Study 1: Juvenile toxicity study. Study 2: Juvenile toxicity study to evaluate deaths.
Clinical	2	Study 3: Uncontrolled, non-randomized, open label dose-escalation trial to evaluate safety, pharmacokinetics and activity of ombrabulin and a combination of ombrabulin with vincristine and irinotecan in children with refractory or relapsed solid tumours. Study 4: Double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of ombrabulin in combination with vincristine and irinotecan in children with rhabdomyosarcoma and non-rhabdomyosarcoma.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By Dec 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes